FDA Adverse Event Injury Summary report: N

XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 2970209 · Received February 20, 2013

Report

Report Number
2024168-2013-00993
Event Type
Injury
Date Received
February 20, 2013
Date of Event
January 25, 2013
Report Date
January 28, 2013
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. THERE WAS NO REPORTED PRODUCT DEFICIENCY AND THE PRODUCT WAS NOT RETURNED. THE REPORTED PATIENT EFFECT OF DISSECTION, AS LISTED IN THE XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM INSTRUCTIONS FOR USE IS A KNOWN ADVERSE EVENT ASSOCIATED WITH CORONARY STENTING PROCEDURES. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS AND THE RELATIONSHIP TO THE DEVICE, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURE, DESIGN OR LABELING.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PROCEDURE WAS TO TREAT AN 80% STENOSED LESION IN THE MID LEFT ANTERIOR DESCENDING ARTERY WITH MODERATE TORTUOSITY. THE 3.0 X 15 MM XIENCE PRIME STENT WAS IMPLANTED; HOWEVER, A PROXIMAL EDGE DISSECTION OCCURRED. THE DISSECTION WAS TREATED WITH AN ADDITIONAL STENT. THERE WERE NO ADVERSE PATIENT EFFECTS AND NO CLINICALLY SIGNIFICANT DELAY IN THE PROCEDURE. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
73038 XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 2072741

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention